Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
Clinical trial NCT05188508 · RECRUITING
Trial details
- NCT number
- NCT05188508
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-14
- Primary completion
- 2027-01-01
- Enrollment
- 57
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.